

Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study

AUTHORS

^{1*}Lita Araujo, MSc, PhD; ¹Svend S Geertsen, PhD; ^{1,2}Allen Amedume, PharmD; ¹Keiko Higuchi, MPH, PhD; ³Janneke van Wingerden, MSc

AUTHORS' AFFILIATIONS

¹Sanofi, Cambridge, MA, US

²School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences (MCPHS) University, Boston, MA, US

³Sanofi, Amsterdam, The Netherlands

*Corresponding author

Lita Araujo, MSc, PhD, lita.araujo@sanofi.com (ORCID ID: 0000-0002-6863-9340)

Svend Sparre Geertsen, PhD, svend.geertsen@sanofi.com (ORCID ID: 0000-0003-4497-3616)

Allen Amedume, PharmD, allen.amedume@sanofi.com

Keiko Higuchi, MPH, PhD, keiko.higuchi@sanofi.com

Janneke van Wingerden, MSc, janneke.wingerden@sanofi.com

Supplementary Material Table 1. National Drug Codes for study DMTs

Generic name	Brand name	Format	Dosage	NDCs
Teriflunomide	Aubagio	Tablet	7 mg	58468021101
				58468021104
			14 mg	58468021002
				58468021004
Dimethyl fumarate	Tecfidera	Delayed-release capsule	120 mg	00378039614
				00093921841
				24979012721
				67877055514
				68180077614
				16729041604
				69238131804
				31722065731
				69097032289
				43598042952
			644060000501	
			240 mg	00378039991
				51407044160
				00093921906
				24979012804
				67877055660
				68180077707
				16729041712
				16729041759
				69238131906
31722065832				
69097032303				
43598043060				
644060000602				

			120-240 mg	67877055739
				68180077813
				69238162603
				31722068060
				69097055203
				644060000703
Diroximel fumarate	Vumerity	Delayed-release capsule	231 mg	644060002003
				644060002001
Fingolimod	Gilenya	Tablet	0.5 mg	000780060715
				000780060751
Cladribine	Mavenclad	Tablet	10 mg	44087040004
				44087400004
				44087040005
				44087400005
				44087040006
				44087400006
				44087040007
				44087400007
				44087040008
				44087400008
				44087040009
				44087400009
				44087040010
				44087400000
Natalizumab	Tysabri	Injectable	300 mg/15 mL	590750073015
				644060000801
Ocrelizumab	Ocrevus	Injectable	300 mg/10 mL	502420015001

NDC, national drug code; DMT, disease-modifying therapy.

Supplementary Material Table 2. Procedure codes for DMTs administered in the clinical setting

Generic name	Procedure code
Natalizumab	C9126 (injection)
	J2323 (injection, 1mg)
Ocrelizumab	J2350 (injection, 1mg)
	C9494 (injection, 1mg)

DMT, disease-modifying therapy.